BENITIONSClinical Trial Intelligence

A Study on the Immunogenicity and Safety of 3 Different Dose Concentrations of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers

3상 조기 종료 NCT06705140

대상 질환RSV Immunisation, Healthy Volunteers
임상 단계3상
스폰서Sanofi Pasteur, a Sanofi Company
상태조기 종료
참여자 수42 명
중재(약물)Low Dose (LD) RSVt vaccine, Standard Dose (SD) RSVt vaccine, High Dose (HD) RSVt vaccine
시작일2024년 11월 25일
완료일2025년 6월 11일
결과 공개일2026년 8월 3일

요약

This study was a Phase III, parallel group, randomized, observer blind, placebo controlled, multi-national, multi-center, multi-arm study conducted in 42 healthy children enrolled at 6 months to \<22 months of age. The purpose of the study was to evaluate the non-inferiority of the immune response of the lower dose (LD) when compared to the standard dose (SD) respiratory syncytial virus infant and toddler (RSVt) vaccine and the safety of the LD, SD and high dose (HD) vaccine in preterm born children and of the HD vaccine in full term born children administered by intranasal route and compared to placebo.

Cohort 2: Geometric Mean Titers (GMT) of RSV A Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)

Day 85 (28 days post-vaccination 2)

Cohort 2: Geometric Mean Titers of RSV B Serum Neutralizing Antibodies at Day 85 (Post-Dose 2)

Day 85 (28 days post-vaccination 2)

Cohorts 1 and 2: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

Up to 30 minutes after each vaccination (post-dose on Day 1) · Participants

Cohort 1: Group 1: Standard Dose RSVt0 Participants
Cohort 1: Group 2: Placebo0 Participants
Cohort 2: Group 1: Low Dose RSVt0 Participants
Cohort 2: Group 2: Standard Dose RSVt0 Participants
Cohort 2: Group 3: High Dose RSVt0 Participants
Cohort 2: Group 4: Placebo0 Participants

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

전체 임상

이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.